Alterations in the fibrinolytic system components during acute myocardial infarction

Acta Cardiologica

Volumn 55, Issue 4, 2000, Pages 247-253

  Ioannidou Papayannaki, E ^a   Lefkos, N ^a   Boudonas, G ^a   Efthimiadis, A ^a   Psirropoulos, D ^a   Vogas, V ^a   Papadopoulos, I ^a   Klonizakis, I ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

AMI; CAD; D Dimer; Fibrinolytic system; PAI I; t PA; Thrombolysis

Indexed keywords

ALTEPLASE; CREATINE KINASE; D DIMER; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMINOGEN ACTIVATION;

EID: 0033777017     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.55.4.2005747     Document Type: Article

References (21)

1. Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-I) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomized, placebo-controlled study
2. Plasma levels of plasminogen activator inhibitor type 1, β-thromboglobulin, and fibrinopeptide A, before, during and after treatment of acute myocardial infarction with alteplase
3. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue type plasminogen activator in patients with acute myocardial infarction
4. Early patency and reocclusion: Comparison of saruplase and alteplase in acute myocardial infarction: From the SESAM Study
5. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial
6. Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: Five-year result of the PRIMI Trial
7. Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy
8. Thrombin-antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis
9. Variation in thrombolytic activity after acute myocardial infarction and after the administration of oral anticoagulant drugs and intravenous heparin
10. Plasma fibrinolytic activity following recent myocardial and cerebral infarction
11. Elevated levels of the rapid inhibitor of plasminogen activator
12. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial re-infarction
13. Predictive value for thrombotic disease of plasminogen activator inhibitor - 1 Plasma levels
14. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
15. Clinical usefulness of D-Dimer. Evaluation during fibrinolytic treatment of venous thrombosis or myocardial infarction
16. Plasma levels of fragment d-dimer or cross-linked fibrin during thrombolytic therapy with recombinant tissue-type plasminogen activator
17. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation
18. Measurement of cross-linked fibrin derivatives in plasma: An immunoassay using monoclonal antibodies
19. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction
20. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of endothelium
21. Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts